Fairvalue-Calculator Fairvalue-Calculator
EN DE

CytoMed Therapeutics Limited (GDTC) Fair Value & Analysis

Healthcare · US · Market cap $13.0M

Price$0.9900
Fair Value$0.2200
Upside-77.8%
Quality89/100
Evidence: Low Range $0.1400 – $0.2700

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

CytoMed Therapeutics Limited (GDTC) currently trades at $0.9900, while our model-based Fair Value estimate is $0.2200 — implying the stock looks roughly 77.8% overvalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for …

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is CytoMed Therapeutics Limited (GDTC) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.2200 versus a price of $0.9900 — about −78% (overvalued). Model-based estimate, not financial advice.
What is the fair value of GDTC?
Our 21-model fair value for CytoMed Therapeutics Limited is $0.2200 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.9900.
What is the quality score of GDTC?
CytoMed Therapeutics Limited has a Quality Score of 89/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.